Comparison of Aptamer-Based and Antibody-Based Assays for Protein Quantification in Chronic Kidney Disease.
AASK (African American Study of Kidney Disease and Hypertension)
antibodies
biological assay
chronic inflammation
chronic kidney disease
end-stage renal disease
mortality
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
02
09
2021
accepted:
14
01
2022
pubmed:
25
2
2022
medline:
23
4
2022
entrez:
24
2
2022
Statut:
ppublish
Résumé
Novel aptamer-based technologies can identify >7000 analytes per sample, offering a high-throughput alternative to traditional immunoassays in biomarker discovery. However, the specificity for distinct proteins has not been thoroughly studied in the context of CKD. We assessed the use of SOMAscan, an aptamer-based technology, for the quantification of eight immune activation biomarkers and cystatin C among 498 African American Study of Kidney Disease and Hypertension (AASK) participants using immunoassays as the gold standard. We evaluated correlations of serum proteins as measured by SOMAscan versus immunoassays with each other and with iothalamate-measured GFR. We then compared associations between proteins measurement with risks of incident kidney failure and all-cause mortality. Six biomarkers (IL-8, soluble TNF receptor superfamily member 1B [TNFRSF1B], cystatin C, soluble TNF receptor superfamily member 1A [TNFRSF1A], IL-6, and soluble urokinase-type plasminogen activator receptor [suPAR]) had non-negligible correlations ( SOMAscan is an efficient and relatively reliable technique for quantifying IL-8, TNFRSF1B, cystatin C, and TNFRSF1A in CKD and detecting their potential associations with clinical outcomes. This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_02_23_CJN11700921.mp3.
Sections du résumé
BACKGROUND AND OBJECTIVES
Novel aptamer-based technologies can identify >7000 analytes per sample, offering a high-throughput alternative to traditional immunoassays in biomarker discovery. However, the specificity for distinct proteins has not been thoroughly studied in the context of CKD.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS
We assessed the use of SOMAscan, an aptamer-based technology, for the quantification of eight immune activation biomarkers and cystatin C among 498 African American Study of Kidney Disease and Hypertension (AASK) participants using immunoassays as the gold standard. We evaluated correlations of serum proteins as measured by SOMAscan versus immunoassays with each other and with iothalamate-measured GFR. We then compared associations between proteins measurement with risks of incident kidney failure and all-cause mortality.
RESULTS
Six biomarkers (IL-8, soluble TNF receptor superfamily member 1B [TNFRSF1B], cystatin C, soluble TNF receptor superfamily member 1A [TNFRSF1A], IL-6, and soluble urokinase-type plasminogen activator receptor [suPAR]) had non-negligible correlations (
CONCLUSIONS
SOMAscan is an efficient and relatively reliable technique for quantifying IL-8, TNFRSF1B, cystatin C, and TNFRSF1A in CKD and detecting their potential associations with clinical outcomes.
PODCAST
This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_02_23_CJN11700921.mp3.
Identifiants
pubmed: 35197258
pii: 01277230-202203000-00006
doi: 10.2215/CJN.11700921
pmc: PMC8975030
doi:
Substances chimiques
Biomarkers
0
Cystatin C
0
Interleukin-8
0
Receptors, Tumor Necrosis Factor
0
Receptors, Urokinase Plasminogen Activator
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-360Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK048689
Pays : United States
Organisme : NCRR NIH HHS
ID : P20 RR011104
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK079310
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106962
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK117068
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000071
Pays : United States
Organisme : NCRR NIH HHS
ID : P20 RR011145
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL155861
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK057867
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000052
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR029887
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK002818
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000827
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000080
Pays : United States
Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
Dubin RF, Rhee EP: Proteomics and metabolomics in kidney disease, including insights into etiology, treatment, and prevention. Clin J Am Soc Nephrol 15: 404–411, 2020
Ellington AA, Kullo IJ, Bailey KR, Klee GG: Antibody-based protein multiplex platforms: Technical and operational challenges. Clin Chem 56: 186–193, 2010
Juncker D, Bergeron S, Laforte V, Li H: Cross-reactivity in antibody microarrays and multiplexed sandwich assays: Shedding light on the dark side of multiplexing. Curr Opin Chem Biol 18: 29–37, 2014
Pertea M, Salzberg SL: Between a chicken and a grape: Estimating the number of human genes. Genome Biol 11: 206, 2010
Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, Keeney TR, Kim N, Saccomano NA, Wilcox SK, Zichi D, Sanders GM: From SOMAmer-based biomarker discovery to diagnostic and clinical applications: A SOMAmer-based, streamlined multiplex proteomic assay. PLoS One 6: e26332, 2011
Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA, Levin S, Black B, Harbut M, Carbone M, Goparaju C, Pass HI: Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 7: e46091, 2012
Petek LM, Rickard AM, Budech C, Poliachik SL, Shaw D, Ferguson MR, Tawil R, Friedman SD, Miller DG: A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 26: 405–413, 2016
Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S, Johnston C, Killick R, Simmons A, Westman E, Hodges A, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Dobson RJ; AddNeuroMed Consortium: Alzheimer’s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement 10: 724–734, 2014
Webber J, Stone TC, Katilius E, Smith BC, Gordon B, Mason MD, Tabi Z, Brewis IA, Clayton A: Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform. Mol Cell Proteomics 13: 1050–1064, 2014
Chen TK, Estrella MM, Appel LJ, Coresh J, Luo S, Reiser J, Obeid W, Parikh CR, Grams ME: Biomarkers of immune activation and incident kidney failure with replacement therapy: Findings from the African American Study of Kidney Disease and Hypertension. Am J Kidney Dis 78: 75–84.e1, 2021
Ishigami J, Taliercio J, I Feldman H, Srivastava A, Townsend R, L Cohen D, Horwitz E, Rao P, Charleston J, Fink JC, Ricardo AC, Sondheimer J, Chen TK, Wolf M, Isakova T, Appel LJ, Matsushita K; CRIC Study Investigators: Inflammatory markers and incidence of hospitalization with infection in chronic kidney disease. Am J Epidemiol 189: 433–444, 2020
Luo S, Coresh J, Tin A, Rebholz CM, Chen TK, Hayek SS, Tracy M, Lipkowitz MS, Appel LJ, Levey AS, Inker LA, Reiser J, Grams ME: Soluble urokinase-type plasminogen activator receptor in Black Americans with CKD. Clin J Am Soc Nephrol 13: 1013–1021, 2018
Chen TK, Estrella MM, Appel LJ, Coresh J, Luo S, Obeid W, Parikh CR, Grams ME: Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality. Nephrol Dial Transplant 36: 561–563, 2021
Wright Jr. JT, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R: Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) pilot study. Control Clin Trials 17 [Suppl]: 3S–16S, 1996
Appel LJ, Wright Jr. JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918–929, 2010
Wright Jr. JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421–2431, 2002
Bhavsar NA, Appel LJ, Kusek JW, Contreras G, Bakris G, Coresh J, Astor BC; AASK Study Group: Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis 58: 886–893, 2011
Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce 3rd RD, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51: 395–406, 2008
Zellner A: An efficient method of estimating seemingly unrelated regressions and tests for aggregation bias. J Am Stat Assoc 57: 348–368, 1962
Zellner A, Huang DS: Further properties of efficient estimators for seemingly unrelated regression equations. Int Econ Rev 3: 300–313, 1962
Zellner A: Estimators for seemingly unrelated regression equations: Some exact finite sample results. J Am Stat Assoc 58: 977–992, 1963
Kukova LZ, Mansour SG, Coca SG, de Fontnouvelle CA, Thiessen-Philbrook HR, Shlipak MG, El-Khoury JM, Parikh CR: Comparison of urine and plasma biomarker concentrations measured by aptamer-based versus immunoassay methods in cardiac surgery patients. J Appl Lab Med 4: 331–342, 2019
Lim SY, Lee JH, Welsh SJ, Ahn SB, Breen E, Khan A, Carlino MS, Menzies AM, Kefford RF, Scolyer RA, Long GV, Rizos H: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomark Res 5: 32, 2017
Raffield LM, Dang H, Pratte KA, Jacobson S, Gillenwater LA, Ampleford E, Barjaktarevic I, Basta P, Clish CB, Comellas AP, Cornell E, Curtis JL, Doerschuk C, Durda P, Emson C, Freeman CM, Guo X, Hastie AT, Hawkins GA, Herrera J, Johnson WC, Labaki WW, Liu Y, Masters B, Miller M, Ortega VE, Papanicolaou G, Peters S, Taylor KD, Rich SS, Rotter JI, Auer P, Reiner AP, Tracy RP, Ngo D, Gerszten RE, O’Neal WK, Bowler RP; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium: Comparison of proteomic assessment methods in multiple cohort studies. Proteomics 20: e1900278, 2020
Tin A, Yu B, Ma J, Masushita K, Daya N, Hoogeveen RC, Ballantyne CM, Couper D, Rebholz CM, Grams ME, Alonso A, Mosley T, Heiss G, Ganz P, Selvin E, Boerwinkle E, Coresh J: Reproducibility and variability of protein analytes measured using a multiplexed modified aptamer assay. J Appl Lab Med 4: 30–39, 2019
Abraham AG, Xu Y, Roem JL, Greenberg JH, Weidemann DK, Sabbisetti VS, Bonventre JV, Denburg M, Warady BA, Furth SL: Variability in CKD biomarker studies: Soluble urokinase plasminogen activator receptor (suPAR) and kidney disease progression in the Chronic Kidney Disease in Children (CKiD) study. Kidney Med 3: 712–721.e1, 2021
Winnicki W, Sunder-Plassmann G, Sengölge G, Handisurya A, Herkner H, Kornauth C, Bielesz B, Wagner L, Kikić Ž, Pajenda S, Reiter T, Schairer B, Schmidt A: Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis and impact of detection method. Sci Rep 9: 13783, 2019
Christensson A, Ash JA, DeLisle RK, Gaspar FW, Ostroff R, Grubb A, Lindström V, Bruun L, Williams SA: The impact of the glomerular filtration rate on the human plasma proteome. Proteomics Clin Appl 12: e1700067, 2018
Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C, Jonasson C, Sarzynski MA, Shipley MJ, Alexander L, Ash J, Bauer T, Chadwick J, Datta G, DeLisle RK, Hagar Y, Hinterberg M, Ostroff R, Weiss S, Ganz P, Wareham NJ: Plasma protein patterns as comprehensive indicators of health. Nat Med 25: 1851–1857, 2019
Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, Rothenbacher D, Sarnak MJ, Astor BC, Coresh J, Levey AS, Gansevoort RT; CKD Prognosis Consortium: Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369: 932–943, 2013
Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke H-D, Tribouilloy C, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox): Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77: 550–556, 2010
Hardikar S, Song X, Kratz M, Anderson GL, Blount PL, Reid BJ, Vaughan TL, White E: Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. Cancer Causes Control 25: 969–976, 2014
Gong Y, Liang S, Zeng L, Ni Y, Zhou S, Yuan X: Effects of blood sample handling procedures on measurable interleukin 6 in plasma and serum. J Clin Lab Anal 33: e22924, 2019
Kordulewska NK, Topa J, Tańska M, Cieślińska A, Fiedorowicz E, Jarmołowska B: Stability of interleukin-1β, -4, -6, -8, -10, -13, interferon-γ and tumor necrosis factor-α in human sera after repetitive freeze-thaw cycles and long storage. J Pharm Biomed Anal 196: 113900, 2021
Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J: Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 52: 1284–1293, 2006
Odden N, Henriksen T, Mørkrid L: Serum soluble urokinase plasminogen activator receptor (suPAR) in early pregnancy prior to clinical onset of preeclampsia. Acta Obstet Gynecol Scand 91: 1226–1232, 2012
Ishigami J, Karger AB, Lutsey PL, Coresh J, Matsushita K: Stability of serum bone-mineral, kidney, and cardiac biomarkers after a freeze-thaw cycle: The ARIC study [published online ahead of print October 13, 2021]. Am J Epidemiol 10.1093/aje/kwab251
doi: 10.1093/aje/kwab251
Elshal MF, McCoy JP: Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA. Methods 38: 317–323, 2006
Hossain MA, Emara M, El Moselhi H, Shoker A: Comparing measures of cystatin C in human sera by three methods. Am J Nephrol 29: 381–391, 2009
Dabitao D, Margolick JB, Lopez J, Bream JH: Multiplex measurement of proinflammatory cytokines in human serum: Comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. J Immunol Methods 372: 71–77, 2011